{
    "clinical_study": {
        "@rank": "168180", 
        "arm_group": [
            {
                "arm_group_label": "Placebo controlled", 
                "arm_group_type": "Active Comparator", 
                "description": "comparison of placebo controlled to 1mg melatonin or 3mg melatonin"
            }, 
            {
                "arm_group_label": "Melatonin", 
                "arm_group_type": "Active Comparator", 
                "description": "comparison of melatonin 1mg or melatonin 3mg"
            }
        ], 
        "brief_summary": {
            "textblock": "The study will evaluate the safety and efficacy of melatonin supplementation in CKD and ESRD\n      patients with sleep disorders to reduce sleep latency times, the number of apnea/hypopneic\n      episodes, and prolong duration in rapid eye movement (REM) sleep in CKD and ESRD patients\n      with sleep disordered breathing."
        }, 
        "brief_title": "Different Doses of Oral Melatonin Supplements in Chronic Kidney Disease (CKD)-Associated Sleep Disorders", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "End Stage Renal Disease", 
            "Chronic Kidney Disease", 
            "Sleep Disorder"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Kidney Diseases", 
                "Kidney Failure, Chronic", 
                "Sleep Disorders", 
                "Parasomnias", 
                "Renal Insufficiency, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Patient age > 18 and <85 years of age\n\n          2. Patients with CKD  or ESRD with eGFR < 30 mls/min\n\n          3. If receiving hemodialysis, patients must be on treatment > 3 months\n\n          4. Normal healthy controls must be without a known history of CKD and be willing to have\n             formal PSG test and plasma melatonin measurements\n\n        Exclusion Criteria:\n\n          1. Patients receiving outpatient hemodialysis for < 3 months\n\n          2. Patients with estimated GFR by Cockcroft Gault > 30 mls/min\n\n          3. Patients receiving beta blocker therapy within one month of randomization\n\n          4. Patients receiving Nifedipine therapy within one month randomization\n\n          5. Patients on peritoneal dialysis\n\n          6. Patient with chronic home oxygen supplementation\n\n          7. Patients receiving chronic home CPAP therapy\n\n          8. Patients actively receiving outpatient sleep medications\n\n          9. Patients with diabetic gastroparesis unresponsive to medication\n\n         10. Patients with known pregnancy or unwilling to use contraception during the course of\n             the study\n\n         11. Patients with a functioning renal allograft\n\n         12. Patient currently receiving long-term immunosuppressive therapy.  Patients receiving\n             low dose prednisone (10mg or less per day) will not be excluded from this trial\n\n         13. Unable to give informed consent"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "53", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01922999", 
            "org_study_id": "Melatonin"
        }, 
        "intervention": {
            "arm_group_label": [
                "Placebo controlled", 
                "Melatonin"
            ], 
            "description": "patients will receive placebo, 1mg melatonin or 3mg melatonin", 
            "intervention_name": "Melatonin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Melatonin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 13, 2014", 
        "location": {
            "contact": {
                "email": "jamestumlinmd@nephassociates.com", 
                "last_name": "James A Tumlin, MD", 
                "phone": "423-826-8003"
            }, 
            "contact_backup": {
                "email": "jeremywhitson@nephassociates.com", 
                "last_name": "Jeremy Whitson", 
                "phone": "423-826-8003"
            }, 
            "facility": {
                "address": {
                    "city": "Chattanooga", 
                    "country": "United States", 
                    "state": "Tennessee", 
                    "zip": "37408"
                }, 
                "name": "Southeast Renal Research Institute"
            }, 
            "investigator": {
                "last_name": "James A Tumlin, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Prospective, Double Blind, Placebo-Controlled Trial of Two Different Doses of Oral Melatonin Supplements in Chronic Kidney Disease (CKD)-Associated Sleep Disorders", 
        "overall_contact": {
            "email": "jamestumlinmd@nephassociates.com", 
            "last_name": "James A Tumlin, MD", 
            "phone": "423-826-8003"
        }, 
        "overall_contact_backup": {
            "email": "jeremywhitson@nephassociates.com", 
            "last_name": "Jeremy Whitson", 
            "phone": "423-826-8003"
        }, 
        "overall_official": {
            "affiliation": "Southeast Renal Research Institute", 
            "last_name": "James A Tumlin, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Patients taking melatonin supplement, 1mg or 3mg daily, compared to placebo controlled group will be compared to see who group achieved a 25% reduction in sleep latency or 25% increase in total sleep time at the end of 60 days.  Using the Pittsburg Sleep Quality Index (PSQI) questionnaire as the index to measure quality of sleep and sleep patterns. Study will also use Polysomnography testing that will record duration of sleep patterns.", 
            "measure": "Primary Objective", 
            "safety_issue": "No", 
            "time_frame": "Compare sleep duration at the end of 60 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01922999"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Southeast Renal Research Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Southeast Renal Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}